Nutropin Depot discontinued
Executive Summary
Genentech/Alkermes are discontinuing injectable human growth hormone Nutropin Depot for commercial reasons. Original form of somatropin and other delivery systems will continue to be available. Nutropin Depot represents less than 5% of Genentech's growth hormone sales, which totaled $85.5 mil. in the first quarter. Alkermes said the Nutropin Depot agreement was not profitable. Genentech is also in the midst of discontinuing the older human growth hormone brand Protropin (somatrem)...
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.